Integra Lifesciences Holdings (IART) Depreciation & Amortization (CF) (2009 - 2020)

Integra Lifesciences Holdings has disclosed Depreciation & Amortization (CF) across 12 years of filings, most recently posting $29.7 million for Q2 2020.

• In Q2 2020, Depreciation & Amortization (CF) rose 10.35% year-over-year to $29.7 million; the TTM figure through Mar 2021 stood at $29.7 million (down 73.39% YoY), while the FY2019 annual figure was $109.5 million, down 1.15% from the prior year.
• Depreciation & Amortization (CF) came in at $29.7 million for Q2 2020 at Integra Lifesciences Holdings, up from $29.2 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $29.7 million in Q2 2020 to a low of $18.0 million in Q2 2016.
• Average Depreciation & Amortization (CF) over 5 years is $24.5 million, with a median of $26.9 million recorded in 2018.
• Year-over-year, Depreciation & Amortization (CF) surged 54.69% in 2016 and decreased 5.0% in 2019.
• Over 5 years, Depreciation & Amortization (CF) stood at $18.3 million in 2016, then soared by 45.61% to $26.7 million in 2017, then gained by 3.8% to $27.7 million in 2018, then advanced by 0.73% to $27.9 million in 2019, then advanced by 6.45% to $29.7 million in 2020.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $29.7 million in Q2 2020, $29.2 million in Q1 2020, and $27.9 million in Q4 2019.